Celsion (CLSN) Trading 11.7% Higher
Celsion Co. (NASDAQ:CLSN) shares traded up 11.7% during trading on Thursday . The stock traded as high as $2.93 and last traded at $2.87. 1,350,700 shares traded hands during mid-day trading, a decline of 14% from the average session volume of 1,562,792 shares. The stock had previously closed at $2.57.
Several research analysts have recently commented on the company. ValuEngine raised Celsion from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Zacks Investment Research raised Celsion from a “sell” rating to a “hold” rating in a report on Tuesday, December 19th. Oppenheimer assumed coverage on Celsion in a report on Tuesday, November 21st. They issued an “outperform” rating and a $9.00 target price on the stock. Finally, Maxim Group raised Celsion from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Wednesday, October 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Celsion currently has an average rating of “Buy” and a consensus target price of $11.90.
An institutional investor recently raised its position in Celsion stock. Renaissance Technologies LLC lifted its holdings in Celsion Co. (NASDAQ:CLSN) by 100.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,375,147 shares of the biotechnology company’s stock after acquiring an additional 690,349 shares during the quarter. Renaissance Technologies LLC owned approximately 2.48% of Celsion worth $397,000 at the end of the most recent reporting period. Institutional investors own 3.97% of the company’s stock.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.